Equillium announces publication of data in the journal of clinical investigation highlighting the importance of the cd6-alcam pathway in the pathogenesis of lupus nephritis

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced publication of a manuscript featured on the front cover of the journal of clinical investigation (www.jci.org/this-month), confirming the role of t cells activated by the cd6-alcam pathway in the development of lupus nephritis (ln). the newly published data supports equill
EQ Ratings Summary
EQ Quant Ranking